Clinical trials: Healthy Adults
Chikungunya Virus
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 (CHIKV VLP vaccine) in healthy adult and adolescent subjects.
- Trial name
- NCT05072080
- Testing
- CHIKV VLP/adjuvant
- Where
- 47 sites in United States
- Volunteers
- 3,258 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Malaria
Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali
Background: Malaria is a disease spread by mosquitos. Pregnant women are highly susceptible to malaria. This can lead to poor health outcomes for pregnant women and their babies.
- Trial name
- NCT03989102
- Testing
- PfSPZ Vaccine, Normal Saline
- Where
- Mali
- Volunteers
- 324 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes
Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D)
In this 2-year randomized clinical trial, we will implement and assess the impact of a behavioral/psychoeducational intervention to reduce diabetes distress and improve glycemic outcomes in adolescents and young adults, aged…
- Trial name
- NCT05413239
- Testing
- Psychoeducation to reduce diabetes distress and improve glycemic outcomes
- Where
- 2 sites in United States
- Volunteers
- 217 people
- Sponsor
- Joslin Diabetes Center
Healthy
Study of ALXN1820 in Healthy Adult Participants
This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ALXN1820…
- Trial name
- NCT04631562
- Testing
- ALXN1820 SC, ALXN1820 IV
- Where
- 3 sites in Australia, United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Meningococcal Immunisation (Healthy Volunteers)
Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age
Primary Objective: To demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W)…
- Trial name
- NCT04368429
- Testing
- Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine), Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- Where
- 4 sites in Japan
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Sanofi
Infections, Bacterial
Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects
This is double-blind, randomized, sequential, two part study. Part 1 is a 3 periods, fixed-sequence study and will be conducted to evaluate the pharmacokinetics, safety, and tolerability of the gepotidacin tablet in healthy adult…
- Trial name
- NCT04079790
- Testing
- Gepotidacin
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years
The purpose of this study is to assess the safety of Takeda's tetravalent dengue vaccine (TDV) (previously DENVax) administered subcutaneously in healthy adults and children.
- Trial name
- NCT01511250
- Testing
- TDV
- Where
- 8 sites in Colombia, Puerto Rico and 2 more
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Takeda
Infections, Meningococcal
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the meningococcal conjugate vaccine (MenACWY-TT) co-administered with Boostrix® versus each of the two vaccines given separately in healthy…
- Trial name
- NCT01767376
- Testing
- Meningococcal vaccine GSK134612, Boostrix®
- Where
- 15 sites in Dominican Republic, Germany and 1 more
- Volunteers
- 692 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Immunisation (Healthy Volunteers)
Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)
Primary Objective: To demonstrate the vaccine seroresponse sufficiency of meningococcal serogroups A, C, Y, and W following the administration of a booster dose of meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus…
- Trial name
- NCT04084769
- Testing
- Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine, Meningococcal Group B vaccine (Trumenba®), Meningococcal group B vaccine (Bexsero®)
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Stuttering, Stuttering, Childhood
Speech Processing in Stuttering
This research is being done to better understand stuttering, specifically how people who stutter may process and/or produce speech.
- Conditions
- Stuttering, Stuttering, Childhood, Stuttering, Adult
- Trial name
- NCT04929184
- Testing
- Speech and non-speech tasks
- Where
- 2 sites in United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Streptococcus Pneumoniae Infection, Pneumococcal Infections
Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)
This study is designed to assess the safety, tolerability, and immunogenicity of 5 different formulations of V114 in healthy adults and infants.
- Trial name
- NCT02037984
- Testing
- Prevnar 13®, V114 1x:1x:1x, V114 2x:2x:2x
- Volunteers
- 341 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Meningococcal
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GSK Biologicals' meningococcal vaccine GSK134612 as compared to Menactra® in subjects 10 through 25 years of age.
- Trial name
- NCT01165242
- Testing
- Meningococcal vaccine GSK 134612, Menactra®
- Where
- 32 sites in United States, Canada
- Volunteers
- 1,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Methods of Exercise in Children
Gas Exchange Kinetics and Work Load During Exercise
The purpose of this research study is to understand how different kinds of exercise affect the human body and the health of the heart and lungs.Participants will exercise in different protocols on a bicycle ergometer or…
- Trial name
- NCT03770507
- Testing
- Exercise Training
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00196937
- Testing
- Cervarix
- Where
- 6 sites in Germany, Poland
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease, Meningococcal Meningitis
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
This study is designed to evaluate the immunogenicity and the safety of a quadrivalent vaccine MenACWY-CRM in healthy subjects from 11 to 55 years of age in Korea.
- Trial name
- NCT01274897
- Testing
- Novartis MenACWY-CRM
- Where
- 8 sites in South Korea
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Tetanus, Diphtheria
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects
This was a dose and formulation ranging study to assess the safety and immunogenicity of SP0173 in healthy adolescents, adults, and older adults in the United States (US).
- Conditions
- Tetanus, Diphtheria, Pertussis, Whooping Cough
- Trial name
- NCT02587520
- Testing
- Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3
- Where
- 20 sites in United States
- Volunteers
- 1,363 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)
This study is designed to assess the effect of different dose levels of pneumococcal polysaccharide and adjuvant on the safety and immunogenicity of V114 in healthy adults and infants.
- Trial name
- NCT02531373
- Testing
- V114 Medium Dose, V114 High Dose, V114 Medium Dose with Alternative Carrier Protein
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Inflammatory Bowel Disease
Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy
Many IBD patients take immunosuppressive agents and we are uncertain as to their capacity to mount a truly protective response after vaccination.
- Trial name
- HPV (NCT00727636)
- Testing
- Gardasil vaccine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Boston Children's Hospital
ADHD, Predominantly Hyperactive - Impulsive, Behavior Problems, Child
Triple P forADHD Children's Mothers, Education of Behavioral Problems, and Change in Mothers' Attitude
The goal of this clinical trial is to investigate whether the Triple P program will reduce behavioral problems for ADHD children, improve mothers' sense of competency, and improve their attitudes The main questions it aims to…
- Conditions
- ADHD, Predominantly Hyperactive - Impulsive, Behavior Problems, Child, ADHD - Attention Deficit Disorder With Hyperactivity, Healthy Adult Females
- Trial name
- (ADHD) (NCT07069621)
- Testing
- Triple p level parenting program
- Where
- Palestinian Territories
- Volunteers
- 67 people
- Sponsor
- Palestine Polytechnic University
Zika Virus, Zika Virus Infection
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
This was a multicenter, randomized study to evaluate the safety, immunogenicity, and efficacy of VRC-ZKADNA090-00-VP (Zika virus wildtype DNA vaccine) or placebo.
- Conditions
- Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections
- Trial name
- DNA (NCT03110770)
- Testing
- VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP
- Where
- 17 sites in United States, Brazil and 7 more
- Volunteers
- 2,428 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)